M
Michael J. Zelefsky
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 576
Citations - 38120
Michael J. Zelefsky is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 102, co-authored 549 publications receiving 35684 citations. Previous affiliations of Michael J. Zelefsky include Cornell University & Kettering University.
Papers
More filters
Journal ArticleDOI
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.
Jonathan I. Epstein,Michael J. Zelefsky,Daniel Sjöberg,Joel B. Nelson,Lars Egevad,Cristina Magi-Galluzzi,Andrew J. Vickers,Anil V. Parwani,Victor E. Reuter,Samson W. Fine,James A. Eastham,Peter Wiklund,Misop Han,Chandana A. Reddy,Jay P. Ciezki,Tommy Nyberg,Eric A. Klein +16 more
TL;DR: Looking at outcomes for prostate cancer treated with radical prostatectomy or radiation therapy and validated a new grading system with more accurate grade stratification than current systems, including a simplified grading system of five grades and the lowest grade is 1, as opposed to 6, with the potential to reduce overtreatment of PCa.
Journal ArticleDOI
Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.
Michael J. Zelefsky,Steven A. Leibel,Paul B. Gaudin,Gerald J. Kutcher,Neil E. Fleshner,E. S. Venkatramen,Victor E. Reuter,William R. Fair,C. Clifton Ling,Zvi Fuks +9 more
TL;DR: The data provide evidence for a significant effect of dose escalation on the response of human prostate cancer to irradiation and defines new standards for curative radiotherapy in this disease.
Journal ArticleDOI
Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Andrew J. Stephenson,Peter T. Scardino,Michael W. Kattan,Thomas M. Pisansky,Kevin M. Slawin,Eric A. Klein,Mitchell S. Anscher,Jeff M. Michalski,Howard M. Sandler,Daniel W. Lin,Jeffrey D. Forman,Michael J. Zelefsky,Larry L. Kestin,Claus G. Roehrborn,Charles Catton,Theodore L. DeWeese,Stanley L. Liauw,Richard K. Valicenti,Deborah A. Kuban,Alan Pollack +19 more
TL;DR: Nearly half of patients with recurrent prostate cancer after radical prostatectomy have a long-term PSA response to SRT when treatment is administered at the earliest sign of recurrence, which should prove valuable for medical decision making for patients with a rising PSA level.
Journal ArticleDOI
High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients
Michael J. Zelefsky,Zvi Fuks,Margie Hunt,Yoshiya Yamada,Christine Marion,C. Clifton Ling,Howard Amols,Ennapadam Venkatraman,Steven A. Leibel +8 more
TL;DR: These data demonstrate the feasibility of high-dose IMRT in a large number of patients and demonstrate that short-term PSA control rates seem to be at least comparable to those achieved with three-dimensional conformal radiotherapy at similar dose levels.
Journal ArticleDOI
High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer
Michael J. Zelefsky,Zvi Fuks,Margie Hunt,Henry J. Lee,Danna Lombardi,C. Clifton Ling,Victor E. Reuter,Ennapadam Venkatraman,Steven A. Leibel +8 more
TL;DR: Sophisticated conformal radiotherapy techniques with high dose 3-D conformal and intensity modulated radiation therapy improve the biochemical outcome in patients with favorable, intermediate and unfavorable risk prostate cancer.